Thu, January 4, 2024 | 6:50PM ET

Small caps have appeal after recent pullback; Biotechnology favored within Healthcare

Name: FS Insight
Price range: $$$

Mark L. Newton, CMT ^AC

Head of Technical Strategy

Key Takeaways

SPX, QQQ have shown some healthy consolidation but no technical deterioration

Small-caps look attractive following pullback on rate bounce

Biotechnology preferred within Healthcare following recent sector breakout

Tune in to CNBC at 8:00am EST Friday 1/5 to catch me on Squawk Box.

Small caps have appeal after recent pullback; Biotechnology favored within Healthcare

Technically, our recent consolidation in US risk assets likely marks an attractive opportunity following the huge run-up into late December. SPX has managed to alleviate near-term overbought conditions while weekly momentum and breadth remain bullish. Trends in both US Dollar and Treasury yields remain lower despite recent bounce attempts, and an upcoming pullback in yields should coincide with Equities turning back up to test and exceed late 2023 highs. Bottom line, this New Year’s hangover looks nearly complete

A few near-term Positives to mention:

RSI is no longer overbought on daily nor weekly timeframes on SPY and QQQ.

2^nd largest SPX sector, Healthcare, has just achieved a relative breakout vs SPX

Technology’s pullback failed to do any damage to its relative chart vs. SPX

Trends remain lower in Yields and US Dollar which is supportive of risk assets

Seasonality remains conducive to bullish gains

Many investors and strategists wondered if Small-caps might outperform in 2024 as interest rates started to recede and mean reversion helps to lift some of last year’s chronic underperformers. I agree with this and feel that the recent breakout can’t be considered false, despite weakness in recent weeks.

As daily charts show, prices have given back nearly 25% of the rally from late October, but are nearing key support which should help prices stabilize and turn back higher. My thinking on this is based on a few key metrics:

Weekly momentum remains quite positive on IShares Small-cap ETF, IWM

IWM did achieve a breakout to the highest levels of 2023 ahead of recent weakness

Relative breakout vs. S&P helped momentum on a ratio of Small-caps to SPX turn up sharply. Despite this pullback of late, this bullish momentum has not been reversed

Interest rate trends remain sharply lower since October and bounce has not been sufficient to argue that yields are turning back up

IWM has now given back 25% of prior rally from October. For those who loved Small-caps given the breakout, this recent pullback should make them a better technical risk/reward given ongoing bullish weekly momentum.

My technical target for IWM is $191.50-$193.50 and this range might be reached on Friday, and should be strong support. This would allow IWM to completely fill the gap from 12/13-12/14 and also represents an area of daily Ichimoku support. Thereafter, I expect a push back to new monthly highs into late January.

Russell 2000

IWM vs. Equal-weighted S&P 500 has nearly retraced 50% of gains which should be important

Here’s another perspective of Small-caps, when viewed in relative terms to the Equal-weighted S&P 500. (Ratio chart of IWM to RSP)

As the weekly chart shows below, this ratio moved to the highest levels in more than a year into year-end 2023 before giving back nearly 50% of this outperformance in short order over the last two weeks.

As can be seen below, weekly momentum remains quite positive and should afford buying opportunities for those who might have missed the recent advance and might be looking to add Small-cap exposure.

Overall, I don’t view recent underperformance as being all that damaging for IWM, either in absolute nor in relative terms. Thus, recent weakness should spell opportunity as the risk/reward looks far improved, particularly given the ongoing three-month downtrend in Treasury yields.

IWM / RSP

January seasonality typically shows some early month weakness in Election years before rally resumes

Looking at Election year seasonality going back since 1950, we see that January trajectory can often be a bit choppy, which dovetails with recent US Equity market price action.

Regardless of looking at 70-year history or 90-year history, early January weakness tends to lead higher into mid-month before some Expiration week consolidation.

Thereafter, a strong rally has typically ensued which takes prices back to highs.

Interestingly enough, rallying into late January this year would line up with a possible three-month anniversary of prior October price lows in SPX last year, along with a six-month anniversary of the prior peak from last July. As many investors are aware, three-and six-month anniversaries from prior turning points can often be important to monitor for a potential change of trend.

Additionally, this anniversary would happen to coincide right near the next US Treasury quarterly refunding and last October’s announcement coincided with a fairly pronounced reversal in the bond market.

Overall, I view that US Equities likely bottom by the 8^th day of January, but this month could still offer some choppy trading, if history is any guide, ahead of a month-end rally.

Biotechnology should be favored within Healthcare in January

Biotechnology looks to be finally starting to show some strength following a very lackluster 2023. Similar to Small-caps, Biotech could show some mean reversion and outperform this year as the Healthcare trade begins to kick back into favor.

While Healthcare as a group has gotten stretched lately, and XLV is now trading near three different prominent peaks going back over the last few years, Biotech should be able to relatively outperform.

My thesis is based on rates continuing to slide, along with mean reversion playing out in Biotech stocks this year relative to the broader Healthcare space.

As this weekly relative chart of XBI vs. RSPH shows (SPDR Series Trust S&P Biotech ETF, relative to Equal-weighted Healthcare ETF (by Invesco)), Biotech has been slowly but surely strengthening in recent months.

This downtrend from 2022 was actually exceeded last week in the ratio of Biotech to the broader Healthcare space, which was considered a technical breakout. Moreover, no evidence of any counter-trend exhaustion is present which would argue that this breakout is false (unlike what happened in Spring of 2023)

Bottom line, Biotech should be favored for outperformance in Healthcare in the weeks to come. While Pharmaceutical stocks took an early January lead, I expect this sub-sector relative strength to shift to more Biotech related names in the last few weeks of January.

Note, this also is a Small-cap play, as 80%+ of XBI is comprised of Small and micro-cap stocks.

FAVORITE TECHNICAL NAMES

DYN, VYGR, KROS, ATAI, ARDX, SANA, RXRX, ARWR are some of my technical favorites within the Small-cap Biotechnology space.

Larger Biotech favorites include VRTX, REGN, INCY, EXEL, INSM to name a few.

XBI / RSPH

Disclosures (show)

This research is for the clients of FS Insight only. FSI Subscription entitles the subscriber to 1 user, research cannot be shared or redistributed. For additional information, please contact your sales representative or FS Insight at fsinsight.com.

Analyst Certification (Reg AC)

Mark L. Newton, CMT, the research analyst denoted by an “AC” on the cover of this report, hereby certifies that all of the views expressed in this report accurately reflect his personal views, which have not been influenced by considerations of the firm’s business or client relationships. Neither I, nor a member of my household is an officer, director, or advisory board member of the issuer(s) or has another significant affiliation with the issuer(s) that is/are the subject of this research report. There is a possibility that we will from time to time have long or short positions in, and buy or sell, the securities or derivatives, if any, referred to in this research.

Conflicts of Interest

This research contains the views, opinions and recommendations of FS Insight. At the time of publication of this report, FS Insight does not know of, or have reason to know of any material conflicts of interest.

General Disclosures

FS Insight is an independent research company and is not a registered investment advisor and is not acting as a broker dealer under any federal or state securities laws.

FS Insight is a member of IRC Securities’ Research Prime Services Platform. IRC Securities is a FINRA registered broker-dealer that is focused on supporting the independent research industry. Certain personnel of FS Insight (i.e. Research Analysts) are registered representatives of IRC Securities, a FINRA member firm registered as a broker-dealer with the Securities and Exchange Commission and certain state securities regulators. As registered representatives and independent contractors of IRC Securities, such personnel may receive commissions paid to or shared with IRC Securities for transactions placed by FS Insight clients directly with IRC Securities or with securities firms that may share commissions with IRC Securities in accordance with applicable SEC and FINRA requirements. IRC Securities does not distribute the research of FS Insight, which is available to select institutional clients that have engaged FS Insight.

As registered representatives of IRC Securities our analysts must follow IRC Securities’ Written Supervisory Procedures. Notable compliance policies include (1) prohibition of insider trading or the facilitation thereof, (2) maintaining client confidentiality, (3) archival of electronic communications, and (4) appropriate use of electronic communications, amongst other compliance related policies.

FS Insight does not have the same conflicts that traditional sell-side research organizations have because FS Insight (1) does not conduct any investment banking activities, and (2) does not manage any investment funds.

This communication is issued by FS Insight and/or affiliates of FS Insight. This is not a personal recommendation, nor an offer to buy or sell nor a solicitation to buy or sell any securities, investment products or other financial instruments or services. This material is distributed for general informational and educational purposes only and is not intended to constitute legal, tax, accounting or investment advice.
The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
Intended for recipient only and not for further distribution without the consent of FS Insight.

This research is for the clients of FS Insight only. Additional information is available upon request. Information has been obtained from sources believed to be reliable, but FS Insight does not warrant its completeness or accuracy except with respect to any disclosures relative to FS Insight and the analyst’s involvement (if any) with any of the subject companies of the research. All pricing is as of the market close for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, risk tolerance, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies. The recipient of this report must make its own independent decision regarding any securities or financial instruments mentioned herein. Except in circumstances where FS Insight expressly agrees otherwise in writing, FS Insight is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice, including within the meaning of Section 15B of the Securities Exchange Act of 1934. All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client website, fsinsight.com. Not all research content is redistributed to our clients or made available to third-party aggregators or the media. Please contact your sales representative if you would like to receive any of our research publications.